在我们最新的播客中,Lonza Capsugel 的 Frank Romanski 探讨了患者偏好如何重塑开发策略。Oral delivery is not just a scientific ambition. It is a route to expanding total addressable market and reaching patients who would otherwise go untreated.
Companies are investing heavily in oral biologics because access drives impact. Even with formulation losses, the opportunity to treat more people is compelling.
Listen to the full conversation to understand why oral delivery has become such a strategic priority.
* The presented information was correct and current at the time of publication.
Latest CHI content